Literature DB >> 8304777

Lymphocyte infiltration of the skin in transgenic mice carrying the human interleukin-2 gene.

M Akiyama1, M Yokoyama, M Katsuki, S Habu, T Nishikawa.   

Abstract

Inflammatory lesions of the skin such as erythema, depigmentation and hair loss were observed in C57/BL6(B6) transgenic mice that carried an intact human genomic interleukin-2 gene (gIL-2 transgenic mice). Accumulation of T lymphocytes in the perivascular and periadnexal areas of the dermis was the first change, followed by dermal papillary oedema, which occurred before the development of macroscopic skin lesions. In 3- or 4-week-old transgenic mice with slight erythema and depigmentation of the skin, there was an increase in the number of perivascular lymphocytes accompanied by the diffuse infiltration of neutrophils and monocytes in the damaged skin. These morphological skin changes were not observed in non-transgenic mice, which were bred together with transgenic litter mates. These findings suggest that lymphocyte infiltration of the perivascular space of the skin is a primary event of exogenously introduced human interleukin-2 gene, resulting in secondary cutaneous changes in gIL-2 transgenic mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8304777     DOI: 10.1007/BF00372129

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  21 in total

1.  T-cell growth factor receptor (Tac-antigen) expression in cutaneous lymphoid infiltrates.

Authors:  E Ralfkiaer; G L Wantzin; H Stein; K Thomsen; D Y Mason
Journal:  J Am Acad Dermatol       Date:  1986-10       Impact factor: 11.527

Review 2.  The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses.

Authors:  J J Farrar; W R Benjamin; M L Hilfiker; M Howard; W L Farrar; J Fuller-Farrar
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

3.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

4.  Dermatologic changes associated with interleukin 2 administration.

Authors:  A A Gaspari; M T Lotze; S A Rosenberg; J B Stern; S I Katz
Journal:  JAMA       Date:  1987-09-25       Impact factor: 56.272

5.  Regulation of T-cell receptor gamma-chain RNA expression in murine Thy-1+ dendritic epidermal cells.

Authors:  W A Kuziel; A Takashima; M Bonyhadi; P R Bergstresser; J P Allison; R E Tigelaar; P W Tucker
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

6.  Organization and structure of the mouse interleukin-2 gene.

Authors:  A Fuse; T Fujita; H Yasumitsu; N Kashima; K Hasegawa; T Taniguchi
Journal:  Nucleic Acids Res       Date:  1984-12-21       Impact factor: 16.971

7.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

Authors:  W H West; K W Tauer; J R Yannelli; G D Marshall; D W Orr; G B Thurman; R K Oldham
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

8.  Thy-1+ epidermal cells proliferate in response to concanavalin A and interleukin 2.

Authors:  J L Nixon-Fulton; P R Bergstresser; R E Tigelaar
Journal:  J Immunol       Date:  1986-04-15       Impact factor: 5.422

9.  Lymphocyte infiltration into cerebellum in transgenic mice carrying human IL-2 gene.

Authors:  M Katsuki; M Kimura; M Ohta; H Otani; O Tanaka; T Yamamoto; S Nozawa-Kimura; M Yokoyama; T Nomura; S Habu
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

10.  Effects of the deregulated expression of human interleukin-2 in transgenic mice.

Authors:  Y Ishida; M Nishi; O Taguchi; K Inaba; N Minato; M Kawaichi; T Honjo
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

View more
  1 in total

1.  Impairment of T cell development in deltaEF1 mutant mice.

Authors:  Y Higashi; H Moribe; T Takagi; R Sekido; K Kawakami; H Kikutani; H Kondoh
Journal:  J Exp Med       Date:  1997-04-21       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.